Lyell Immunopharma, Inc. income statement

In fiscal 2025, Lyell Immunopharma, Inc. reported revenue of $36,000, down 41.0% on the year before, operating income of −$269m (a -748344.4% margin) and net income of −$274m, or −$16.06 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Lyell Immunopharma, Inc.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	1	8	11	85	0	0	0	0
Research and development	64	182	139	159	183	172	159	156
General and administrative	39	47	89	117	67	52	45	40
Operating income	−102	−212	−215	−187	−247	−359	−269	−256
Income tax	—	—	—	—	—	—	0	—
Net income	−129	−204	−250	−183	−235	−343	−274	−248
Diluted EPS	−$48.08	−$31.38	−$36.80	−$14.80	−$18.70	−$26.23	−$16.06	−$11.82
Diluted shares (average)	—	7m	7m	12m	13m	13m	17m	21m
EBITDA	−101	−208	−201	−169	−227	−339	−258	−247

US$ millions unless shown otherwise. Fiscal quarters.

Lyell Immunopharma, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	0	0	0	0	0	0
Research and development	40	49	43	35	28	52	37	40
General and administrative	12	15	14	10	11	11	10	10
Operating income	−51	−201	−57	−47	−37	−128	−44	−47
Net income	−45	−192	−52	−43	−39	−141	−24	−45
Diluted EPS	−$3.48	−$14.40	−$3.54	−$2.89	−$2.13	−$7.68	−$1.10	−$1.92
EBITDA	−46	−196	−54	−44	−35	−125	−42	−45

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AIM vs LYEL IBIO vs LYEL LSTA vs LYEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lyell Immunopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lyell Immunopharma, Inc.